- Home
- ALDX vs NCV Comparison
ALDX vs NCV Comparison
Compare ALDX & NCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- NCV
- Stock Information
- Founded
- ALDX 2004
- NCV 2003
- Country
- ALDX United States
- NCV United States
- Employees
- ALDX N/A
- NCV N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- NCV Finance Companies
- Sector
- ALDX Health Care
- NCV Finance
- Exchange
- ALDX Nasdaq
- NCV Nasdaq
- Market Cap
- ALDX 304.9M
- NCV 299.1M
- IPO Year
- ALDX 2014
- NCV N/A
- Fundamental
- Price
- ALDX $6.91
- NCV $12.91
- Analyst Decision
- ALDX Strong Buy
- NCV
- Analyst Count
- ALDX 2
- NCV 0
- Target Price
- ALDX $10.00
- NCV N/A
- AVG Volume (30 Days)
- ALDX 636.8K
- NCV 405.1K
- Earning Date
- ALDX 05-01-2025
- NCV 01-01-0001
- Dividend Yield
- ALDX N/A
- NCV 12.48%
- EPS Growth
- ALDX N/A
- NCV N/A
- EPS
- ALDX N/A
- NCV N/A
- Revenue
- ALDX N/A
- NCV N/A
- Revenue This Year
- ALDX N/A
- NCV N/A
- Revenue Next Year
- ALDX N/A
- NCV N/A
- P/E Ratio
- ALDX N/A
- NCV N/A
- Revenue Growth
- ALDX N/A
- NCV N/A
- 52 Week Low
- ALDX $2.71
- NCV $2.84
- 52 Week High
- ALDX $7.20
- NCV $3.59
- Technical
- Relative Strength Index (RSI)
- ALDX 61.80
- NCV 22.00
- Support Level
- ALDX $6.79
- NCV $12.87
- Resistance Level
- ALDX $7.20
- NCV $13.85
- Average True Range (ATR)
- ALDX 0.56
- NCV 0.22
- MACD
- ALDX 0.03
- NCV -0.08
- Stochastic Oscillator
- ALDX 88.02
- NCV 4.94
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
About NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.